In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones.
“2015 was a very significant year for us at Oramed, setting the bar high for what we anticipate to be a momentous year ahead in 2016,” he added.
Starting out with strong balance sheet with roughly $40-million of cash, Mr. Kidron also updated the clinical status of Oramed’s oral insulin drug candidates – ORMD-0801 and ORMD-0901 – and an out-licensing deal in China.
A copy of the letter can be accessed here.
